Cardiovascular Protective Effects and Clinical Applications of Resveratrol.

Resveratrol is a naturally occurring phenol that is generated by plant species following injury or attack by bacterial and fungal pathogens. This compound was first described as the French Paradox in 1992. Later in 2003, resveratrol was reported to activate sirtuins in yeast cells. Recent experimental studies have found that resveratrol offers a variety of benefits that include both anticarcinogenic and anti-inflammatory effects in addition to the ability to reverse obesity, attenuate hyperglycemia and hyperinsulinemia, protect heart and endothelial function, and increase the life span. Multiple molecular targets are associated with the cardioprotective capabilities of resveratrol, and therefore, resveratrol has potential for a wide range of new therapeutic strategies for atherosclerosis, ischemia/reperfusion, metabolic syndrome, cardiac failure, and inflammatory alterations during aging. Expectations for application in human patients, however, suffer from a lack of sufficient clinical evidence in support of these beneficial effects. This article reviews recently reported basic research results that describe the beneficial effects of resveratrol in an attempt to condense the evidence observed in clinical trials and provide support for the future development of novel clinical therapeutics in patients with cardiovascular diseases.

[1]  M. Brown,et al.  Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. , 1983, Annual review of biochemistry.

[2]  S. Renaud,et al.  Wine, alcohol, platelets, and the French paradox for coronary heart disease , 1992, The Lancet.

[3]  D. Mangelsdorf,et al.  An oxysterol signalling pathway mediated by the nuclear receptor LXRα , 1996, Nature.

[4]  R. Evans,et al.  Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.

[5]  R. Ross Atherosclerosis is an inflammatory disease , 1999 .

[6]  D. Koop,et al.  Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264.7 macrophages. , 1999, Biochemical pharmacology.

[7]  T. Lüscher,et al.  Enhanced Peroxynitrite Formation Is Associated with Vascular Aging , 2000, The Journal of experimental medicine.

[8]  P. Ganz,et al.  Role of Endothelin-1 in the Active Constriction of Human Atherosclerotic Coronary Arteries , 2001, Circulation.

[9]  A. Zeiher,et al.  Aging Enhances the Sensitivity of Endothelial Cells Toward Apoptotic Stimuli: Important Role of Nitric Oxide , 2001, Circulation research.

[10]  Z. Ungvari,et al.  Aging-Induced Phenotypic Changes and Oxidative Stress Impair Coronary Arteriolar Function , 2002, Circulation research.

[11]  T. Willson,et al.  Synthetic LXR ligand inhibits the development of atherosclerosis in mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Antioxidant and diffusion properties of nitric oxide in low-density lipoprotein. , 2002, Methods in enzymology.

[13]  Phuong Chung,et al.  Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan , 2003, Nature.

[14]  T. Hintze,et al.  NAD(P)H oxidase-generated superoxide anion accounts for reduced control of myocardial O2 consumption by NO in old Fischer 344 rats. , 2003, American journal of physiology. Heart and circulatory physiology.

[15]  M. Yen,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. , 2003, Molecular pharmacology.

[16]  T. Cheng,et al.  Inhibition of Cyclic Strain-Induced Endothelin-1 Gene Expression by Resveratrol , 2003, Hypertension.

[17]  Joseph M. Wu,et al.  Effect of red wine and wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits. , 2003, International journal of molecular medicine.

[18]  L. Barenghi,et al.  Resveratrol provides late-phase cardioprotection by means of a nitric oxide- and adenosine-mediated mechanism. , 2003, European journal of pharmacology.

[19]  M. Aviram,et al.  Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. , 2004, Free radical biology & medicine.

[20]  E. Hirsch,et al.  Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence. , 2004, Cardiovascular research.

[21]  A. Csiszar,et al.  Premature death and age-related cardiac dysfunction in male eNOS-knockout mice. , 2004, Journal of molecular and cellular cardiology.

[22]  P. Ganz,et al.  Role of Endothelial Dysfunction in Atherosclerosis , 2004, Circulation.

[23]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[24]  Z. Ungvari,et al.  Proinflammatory phenotype of coronary arteries promotes endothelial apoptosis in aging. , 2004, Physiological genomics.

[25]  S. Nagueh,et al.  Avoiding Papillary Muscle Infarction With Myocardial Contrast Echocardiographic Guidance of Nonsurgical Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy , 2004 .

[26]  Anita Y. M. Chan,et al.  Activation of AMP-activated Protein Kinase Inhibits Protein Synthesis Associated with Hypertrophy in the Cardiac Myocyte* , 2004, Journal of Biological Chemistry.

[27]  K. Reynolds,et al.  Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.

[28]  T. Cheng,et al.  Resveratrol inhibits angiotensin II-induced endothelin-1 gene expression and subsequent proliferation in rat aortic smooth muscle cells. , 2005, European journal of pharmacology.

[29]  Michael Lehrke,et al.  The Many Faces of PPARγ , 2005, Cell.

[30]  Study Yields Murky Signals on Low-Fat Diets and Disease , 2006, Science.

[31]  Ramesh Vidavalur,et al.  Significance of wine and resveratrol in cardiovascular disease: French paradox revisited. , 2006, Experimental and clinical cardiology.

[32]  R. Stocker,et al.  Heme oxygenase-1: a novel drug target for atherosclerotic diseases? , 2006, Circulation.

[33]  Marie Sevov,et al.  Resveratrol regulates the expression of LXR-α in human macrophages , 2006 .

[34]  N. Maulik,et al.  Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1 , 2006, Cell Biochemistry and Biophysics.

[35]  T. Netticadan,et al.  Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. , 2007, American journal of physiology. Heart and circulatory physiology.

[36]  Z. Ungvari,et al.  Increased mitochondrial H2O2 production promotes endothelial NF- B activation in aged rat arteries , 2007 .

[37]  J. Wang,et al.  Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages. , 2007, Journal of applied physiology.

[38]  G. Pierce,et al.  Direct Evidence of Endothelial Oxidative Stress With Aging in Humans: Relation to Impaired Endothelium-Dependent Dilation and Upregulation of Nuclear Factor-&kgr;B , 2007, Circulation research.

[39]  H. Zhen,et al.  New enlightenment of French paradox: Resveratrol's potential for cancer chemoprevention and anti-cancer therapy , 2007, Cancer biology & therapy.

[40]  N. Maulik,et al.  Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. , 2007, Free radical biology & medicine.

[41]  J. Dyck,et al.  Expression of an active LKB1 complex in cardiac myocytes results in decreased protein synthesis associated with phenylephrine-induced hypertrophy. , 2007, American journal of physiology. Heart and circulatory physiology.

[42]  Z. Ungvari,et al.  Dysregulation of mitochondrial biogenesis in vascular endothelial and smooth muscle cells of aged rats. , 2008, American journal of physiology. Heart and circulatory physiology.

[43]  Leonid Peshkin,et al.  Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. , 2008, Cell metabolism.

[44]  E. Lakatta,et al.  Inflammation and endothelial dysfunction during aging: role of NF-kappaB. , 2008, Journal of applied physiology.

[45]  B. Viollet,et al.  Resveratrol Inhibits Cardiac Hypertrophy via AMP-activated Protein Kinase and Akt* , 2008, Journal of Biological Chemistry.

[46]  K. Sunagawa,et al.  SIRT1, a Longevity Gene, Downregulates Angiotensin II Type 1 Receptor Expression in Vascular Smooth Muscle Cells , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[47]  Xiaofan Jiang,et al.  Resveratrol inhibits MMP-9 expression by up-regulating PPAR α expression in an oxygen glucose deprivation-exposed neuron model , 2009, Neuroscience Letters.

[48]  Z. Ungvari,et al.  Resveratrol Improves Endothelial Function: Role of TNFα and Vascular Oxidative Stress , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[49]  Anita Y. M. Chan,et al.  Resveratrol Prevents the Prohypertrophic Effects of Oxidative Stress on LKB1 , 2009, Circulation.

[50]  Z. Ungvari,et al.  Resveratrol Prevents Monocrotaline‐induced Pulmonary Hypertension in Rats , 2008, Hypertension.

[51]  Z. Ungvari,et al.  Resveratrol induces mitochondrial biogenesis in endothelial cells , 2009, American journal of physiology. Heart and circulatory physiology.

[52]  Z. Ungvari,et al.  The Krebs cycle and mitochondrial mass are early victims of endothelial dysfunction: proteomic approach. , 2009, The American journal of pathology.

[53]  Z. Ungvari,et al.  Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells , 2009, American journal of physiology. Heart and circulatory physiology.

[54]  D. Das,et al.  Red wine antioxidant resveratrol-modified cardiac stem cells regenerate infarcted myocardium , 2010, Journal of cellular and molecular medicine.

[55]  Z. Ungvari,et al.  Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging. , 2010, American journal of physiology. Heart and circulatory physiology.

[56]  B. Zhu,et al.  Mechanism for the protective effect of resveratrol against oxidative stress-induced neuronal death. , 2010, Free radical biology & medicine.

[57]  Hope D. Anderson,et al.  Resveratrol and small artery compliance and remodeling in the spontaneously hypertensive rat. , 2010, American journal of hypertension.

[58]  Hope D. Anderson,et al.  Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. , 2010, American journal of hypertension.

[59]  J. Graham,et al.  PPARγ1 and LXRα face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1 , 2010, Nuclear Receptor Signaling.

[60]  D. Kennedy,et al.  Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. , 2010, The American journal of clinical nutrition.

[61]  Simone Fulda,et al.  Resveratrol and derivatives for the prevention and treatment of cancer. , 2010, Drug discovery today.

[62]  U. Förstermann,et al.  Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling , 2011, British journal of pharmacology.

[63]  H. Mukhtar,et al.  Enhancing the bioavailability of resveratrol by combining it with piperine. , 2011, Molecular nutrition & food research.

[64]  T. Iwasaka,et al.  Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. , 2011, Nutrition research.

[65]  A. Reiss,et al.  The ABC transporters in lipid flux and atherosclerosis. , 2011, Progress in lipid research.

[66]  Thomas A. Burgess,et al.  Improving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal muscle. , 2011, Archives of surgery.

[67]  J. Buckley,et al.  Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. , 2011, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[68]  W. Manning,et al.  Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia. , 2011, European journal of pharmacology.

[69]  J. Auwerx,et al.  Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. , 2011, Cell metabolism.

[70]  J. Bhatt,et al.  Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. , 2012, Nutrition research.

[71]  J. Baur,et al.  Challenges of translating basic research into therapeutics: resveratrol as an example. , 2012, The journals of gerontology. Series A, Biological sciences and medical sciences.

[72]  M. Garcia-Conesa,et al.  Grape Resveratrol Increases Serum Adiponectin and Downregulates Inflammatory Genes in Peripheral Blood Mononuclear Cells: A Triple-Blind, Placebo-Controlled, One-Year Clinical Trial in Patients with Stable Coronary Artery Disease , 2012, Cardiovascular Drugs and Therapy.

[73]  S. Banerjee,et al.  Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. , 2012, Pharmacological research.

[74]  Vodka and Wine Consumption in a Swine Model of Metabolic Syndrome Alters Insulin Signaling Pathways in the Liver and Skeletal Muscle , 2012 .

[75]  Y. Taga,et al.  Resveratrol: French Paradox Revisited , 2012, Front. Pharmacol..

[76]  V. Mohan,et al.  Changing definitions of metabolic syndrome , 2012, Indian journal of endocrinology and metabolism.

[77]  Shinichi Nakagawa,et al.  The effect of resveratrol on longevity across species: a meta-analysis , 2012, Biology Letters.

[78]  S. Grundy Pre-diabetes, metabolic syndrome, and cardiovascular risk. , 2012, Journal of the American College of Cardiology.

[79]  Sameer Al-harthi,et al.  Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line , 2012, Cancer Cell International.

[80]  M. Garcia-Conesa,et al.  Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. , 2012, Molecular nutrition & food research.

[81]  Hailiang Zhu,et al.  Derivatives of resveratrol: potential agents in prevention and treatment of cardiovascular disease. , 2012, Current medicinal chemistry.

[82]  A. Reiss,et al.  Resveratrol in cholesterol metabolism and atherosclerosis. , 2012, Journal of medicinal food.

[83]  K. Schechtman,et al.  Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. , 2012, Cell metabolism.

[84]  N. Barzilai,et al.  Pilot study of resveratrol in older adults with impaired glucose tolerance. , 2012, The journals of gerontology. Series A, Biological sciences and medical sciences.

[85]  T. Netticadan,et al.  Resveratrol protects adult cardiomyocytes against oxidative stress mediated cell injury. , 2012, Archives of biochemistry and biophysics.

[86]  K. Magyara,et al.  Cardioprotection by resveratrol : A human clinical trial in patients with stable coronary artery disease , 2012 .

[87]  M. Garcia-Conesa,et al.  One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. , 2012, The American journal of cardiology.

[88]  Ionut Donoiu,et al.  Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. , 2013, Nutrition.

[89]  Xiaojun Yan,et al.  From resveratrol to its derivatives: new sources of natural antioxidant. , 2013, Current medicinal chemistry.

[90]  J. Baur,et al.  Resveratrol for primary prevention of atherosclerosis: clinical trial evidence for improved gene expression in vascular endothelium. , 2013, International journal of cardiology.

[91]  Kaustabh Singh,et al.  Sirtuin 1-mediated Effects of Exercise and Resveratrol on Mitochondrial Biogenesis* , 2013, The Journal of Biological Chemistry.

[92]  Corrigendum to “Effect of flavonoids and Vitamin E on cyclooxygenase-2 (COX-2) transcription” [Mutat. Res. 551 (1–2) (July 2004) 245–254] , 2013 .

[93]  G. Su,et al.  Resveratrol Alleviates Endotoxin-Induced Myocardial Toxicity via the Nrf2 Transcription Factor , 2013, PloS one.

[94]  Jin Han,et al.  HS-1793, a recently developed resveratrol analogue protects rat heart against hypoxia/reoxygenation injury via attenuating mitochondrial damage. , 2013, Bioorganic & medicinal chemistry letters.

[95]  R. Gambino,et al.  Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. , 2013, Current medicinal chemistry.

[96]  J. Buckley,et al.  Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults , 2013, Journal of hypertension.

[97]  J. Smoliga,et al.  A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations , 2013, Aging.

[98]  O. Hai,et al.  Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARγ and adenosine. , 2013, European journal of pharmacology.

[99]  A. Sahebkar Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. , 2013, Nutrition reviews.

[100]  A. Puca,et al.  Resveratrol Improves Vascular Function in Patients With Hypertension and Dyslipidemia by Modulating NO Metabolism , 2013, Hypertension.

[101]  N. Møller,et al.  High-Dose Resveratrol Supplementation in Obese Men , 2013, Diabetes.

[102]  T. Netticadan,et al.  Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic Patients , 2013, Evidence-based complementary and alternative medicine : eCAM.

[103]  V. Dolinsky,et al.  Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. , 2013, Biochimica et biophysica acta.

[104]  R. Ritchie,et al.  Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. , 2014, Pharmacology & therapeutics.

[105]  E. Martínez-Abundis,et al.  Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. , 2013, Metabolic syndrome and related disorders.

[106]  Javed Ali,et al.  Resveratrol: review on therapeutic potential and recent advances in drug delivery , 2014, Expert opinion on drug delivery.

[107]  A. Boffi,et al.  Improved stability of trans-resveratrol in aqueous solutions by carboxymethylated (1,3/1,6)-β-D-glucan. , 2014, Journal of agricultural and food chemistry.

[108]  E. Falk,et al.  Mechanisms of Plaque Formation and Rupture , 2014 .

[109]  Jaspinder Kaur A Comprehensive Review on Metabolic Syndrome , 2014, Cardiology research and practice.

[110]  J. Holloszy,et al.  Multiple dietary supplements do not affect metabolic and cardiovascular health , 2013, Aging.

[111]  S. Anton,et al.  Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study , 2014, Experimental Gerontology.

[112]  Q. Yang,et al.  Resveratrol-enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice , 2014, Journal of cellular and molecular medicine.

[113]  D. DiPette,et al.  Protective effect of resveratrol against pressure overload-induced heart failure , 2014, Food science & nutrition.

[114]  J. Dyck,et al.  Systemic and renal oxidative stress in the pathogenesis of hypertension: modulation of long-term control of arterial blood pressure by resveratrol , 2014, Front. Physiol..

[115]  D. Kennedy,et al.  Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation , 2014, British Journal of Nutrition.

[116]  Meng Chen,et al.  Arsenic Trioxide and Resveratrol Show Synergistic Anti-Leukemia Activity and Neutralized Cardiotoxicity , 2014, PloS one.

[117]  Yanjie Lu,et al.  Resveratrol Attenuated Low Ambient Temperature-Induced Myocardial Hypertrophy via Inhibiting Cardiomyocyte Apoptosis , 2015, Cellular Physiology and Biochemistry.

[118]  I. M. Robertson,et al.  Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. , 2015, Biochimica et biophysica acta.

[119]  Huang-Ping Yu,et al.  Organ-Protective Effects of Red Wine Extract, Resveratrol, in Oxidative Stress-Mediated Reperfusion Injury , 2015, Oxidative medicine and cellular longevity.

[120]  S. He,et al.  Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. , 2015, Clinical nutrition.

[121]  Pál Pacher,et al.  Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. , 2015, Biochimica et biophysica acta.

[122]  J. Viña,et al.  Properties of Resveratrol: In Vitro and In Vivo Studies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans , 2015, Oxidative medicine and cellular longevity.

[123]  T. Netticadan,et al.  Resveratrol is equipotent to perindopril in attenuating post-infarct cardiac remodeling and contractile dysfunction in rats. , 2016, The Journal of nutritional biochemistry.

[124]  C. Zhai,et al.  WITHDRAWN: Resveratrol increases microRNA-130a expression to promote angiogenesis and improve heart functions in mice after myocardial infarction. , 2016, Experimental and molecular pathology.

[125]  J. Zhang,et al.  Resveratrol exerts protective effects on anoxia/reoxygenation injury in cardiomyocytes via miR-34a/Sirt1 signaling pathway. , 2016, European review for medical and pharmacological sciences.

[126]  P. Pasalar,et al.  Effects of Resveratrol on Crosstalk between Canonical Β-Catenin/Wnt and FOXO Pathways in Coronary Artery Disease Patients with Metabolic Syndrome: A Case Control Study , 2016, Iranian journal of pharmaceutical research : IJPR.

[127]  D. Moodie The Global Burden of Cardiovascular Disease. , 2016, Congenital heart disease.

[128]  M. Safar,et al.  The two faces of hypertension: role of aortic stiffness. , 2016, Journal of the American Society of Hypertension : JASH.

[129]  Biao Xu,et al.  Resveratrol ameliorates myocardial fibrosis by inhibiting ROS/ERK/TGF-β/periostin pathway in STZ-induced diabetic mice , 2016, BMC Cardiovascular Disorders.

[130]  Hui Yu,et al.  Resveratrol attenuates high glucose-induced cardiomyocytes injury via interfering ROS-MAPK-NF-κB signaling pathway. , 2018, International journal of clinical and experimental pathology.